Emma H. A. Stahlie

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

Kristy K. Broman, Tasha M. Hughes, Lesly A. Dossett et al. · Cancer · 2021 · 60 citations · Full text

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience

Michael J. Carr, James Sun, Danielle K. DePalo et al. · Annals of Surgical Oncology · 2021 · 40 citations

Surgical Oncology, Medicine, Melanoma +10

T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

Emma H. A. Stahlie, Viola Franke, Charlotte L. Zuur et al. · Cancer Immunology Immunotherapy · 2021 · 35 citations · Full text

Stage Iiib-ivm1a Melanoma, Tumor Load, Medicine +8

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke et al. · BMC Cancer · 2022 · 34 citations · Full text

Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis

Kristy K. Broman, Tasha M. Hughes, Lesly A. Dossett et al. · Journal of the American College of Surgeons · 2020 · 21 citations · Full text